Data Provided by Refinitiv. Minimum 15 minutes delayed.

Immunovaccine to Present at 2016 Biotech & Money Showcase Conference

November 14, 2016 at 12:00 PM EST

Halifax, Nova Scotia; November 14, 2016 – Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced that it will participate in the 2016 Biotech & Money Investival Showcase in London, England. This event is a corporate, investor and networking conference, co-located with the Jefferies 2016 London Healthcare Conference, that gives private and public life sciences companies an opportunity to meet investors and pharmaceutical executives.

Chief Executive Officer Frederic Ors is scheduled to present a corporate overview and update on Friday, November 18 at 2:30 p.m. GMT at The Hilton Waldorf, London.
The presentation will be available on Immunovaccine’s website at following the meeting.  
About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented delivery agent that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1/1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer, as well as a Phase 2 study in recurrent lymphoma. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), and currently has clinical projects ongoing to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at
Contacts for Immunovaccine:
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E:
Frederic Ors, Chief Executive Officer
T: (902) 492-1819 E: